#Newborn Screening Market Technology Insights

[industrynewsupdates]

Role of Technology in the Newborn Screening Market

The global newborn screening market was valued at USD 789.35 million in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 7.54% from 2023 to 2030. This growth is primarily driven by several factors, including an increasing neonatal population, a rising incidence of congenital diseases in newborns, heightened consumer awareness, and supportive initiatives from various governments that are implementing programs and legislations to promote newborn screening. Additionally, advancements in screening technologies are expected to further enhance market growth.

The growing prevalence of congenital diseases among newborns is anticipated to positively impact the newborn screening market. According to data released by the World Health Organization (WHO) in February 2023, approximately 240,000 newborns worldwide die within the first 28 days of life each year due to congenital conditions. These disorders are also linked to around 170,000 child deaths annually among those aged between one month and five years. Furthermore, research from Indian Pediatrics indicates that congenital hypothyroidism occurs in 2.1 out of every 1,000 infants in India, with the prevalence of inborn metabolic disorders ranging from 2% to 7.8%. The significant occurrence of congenital diseases in newborns is likely to drive the demand for testing, thereby accelerating market growth by 2030.

Gather more insights about the market drivers, restrains and growth of the Newborn Screening Market

Technology Insights

In 2022, the tandem mass spectrometry segment emerged as the dominant force in the newborn screening market, capturing 24.5% of the overall revenue share. This leadership position can be attributed to several key factors, including its cost-effectiveness, broader applicability across various testing scenarios, and continuous technological advancements. Tandem mass spectrometry (MS/MS) is particularly valued for its ability to efficiently diagnose a wide range of medical conditions in a single testing procedure, making it an invaluable tool in newborn screening.

The efficiency of tandem mass spectrometry allows healthcare professionals to conduct comprehensive screenings that can identify multiple disorders simultaneously, thereby facilitating timely interventions. As the healthcare landscape evolves, the demand for rapid and accurate diagnostic tools has surged. This trend is likely to propel the tandem mass spectrometry segment to experience substantial growth, with a significant compound annual growth rate (CAGR) projected over the coming years. The innovative advancements being made by key market players are also expected to contribute to this growth. For example, in April 2023, Waters Corporation unveiled its new Xevo TQ Absolute IVD Mass Spectrometer, designed specifically for clinical applications. This product exemplifies the continuous push for technological enhancements that not only improve diagnostic accuracy but also streamline laboratory workflows.

In addition to tandem mass spectrometry, the electrophoresis segment is anticipated to see notable demand, projecting an impressive CAGR of 8.09% throughout the forecast period. The increasing emphasis on early detection techniques in healthcare is a primary driver behind this growth. Early diagnosis is crucial in managing congenital diseases effectively, as it allows for timely treatment and better health outcomes for newborns. Consequently, as healthcare providers and institutions prioritize early intervention strategies, the demand for electrophoresis is expected to rise correspondingly.

The growth of the electrophoresis segment is further supported by a surge in collaborations among various market players. Such partnerships often lead to innovative solutions that enhance product offerings and broaden market reach. For instance, in October 2022, CMP Scientific Corp. entered into a co-marketing agreement with Agilent to promote its advanced electrophoresis system. This collaboration not only aims to improve the technological capabilities of electrophoresis solutions but also focuses on expanding accessibility to these crucial diagnostic tools in newborn screening programs.

Moreover, the increasing focus on research and development in the field of newborn screening technologies is set to further enhance the capabilities of both tandem mass spectrometry and electrophoresis. As new methodologies and products are introduced, healthcare providers will be better equipped to address the complexities associated with congenital diseases. The integration of advanced technologies is expected to foster innovation, leading to more efficient, reliable, and cost-effective solutions for newborn screening.

Order a free sample PDF of the Newborn Screening Market Intelligence Study, published by Grand View Research.

[datalyst]

The Molecular Diagnostics Market: A Deep Dive into Precision Medicine and Technological Advancements

The Molecular Diagnostics Market has emerged as a critical player, driving advancements in precision medicine. This sector's ability to provide specific, reliable, and real-time data at the molecular level has accelerated the development of personalized treatments, enabling clinicians to diagnose diseases earlier and more accurately. From its foundation in genomics to its expanding applications across oncology, infectious diseases, and genetic testing, the molecular diagnostics market is witnessing rapid growth. This blog will explore the molecular diagnostics landscape, its primary technologies, industry growth drivers, and key challenges.

Understanding Molecular Diagnostics

Molecular diagnostics is a field that focuses on analyzing biological markers in the genome and proteome—the individual’s genetic code and how cells express their genes. These diagnostics provide insights into the molecular underpinnings of disease, often involving DNA or RNA detection to understand the health status or predisposition to specific conditions. Unlike traditional diagnostics, molecular diagnostics reveals the root cause at the molecular level, allowing for precise interventions tailored to the patient.

Major Segments in Molecular Diagnostics

The molecular diagnostics market encompasses several segments based on technologies, applications, end-users, and regions.

Technology Key technologies in molecular diagnostics include Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), DNA Microarrays, and In Situ Hybridization (ISH). PCR remains a staple in molecular testing for its simplicity and efficiency, while NGS has unlocked unprecedented possibilities in genomic testing. DNA microarrays, once the go-to technology, continue to play a role in specialized applications, particularly when high-throughput screening is necessary.

Application Applications in molecular diagnostics are vast, with significant focus areas in oncology, infectious disease testing, genetic testing, and pharmacogenomics. Oncology has been one of the fastest-growing applications, given the increasing prevalence of cancers worldwide. In infectious disease testing, molecular diagnostics was instrumental in managing the COVID-19 pandemic, bringing global attention to its capabilities. Genetic testing, which includes prenatal testing and newborn screening, is another vital segment, especially as it enables early disease detection and the potential for preventive care.

End-Users Molecular diagnostics primarily serves hospitals, diagnostic laboratories, academic and research institutes, and even home healthcare setups. Hospitals and diagnostic laboratories account for the highest share due to the need for advanced equipment, high-volume testing, and expert personnel.

The Growth Dynamics of the Molecular Diagnostics Market

The global molecular diagnostics market is projected to grow significantly in the coming years, driven by various factors:

Rising Incidences of Chronic and Infectious Diseases Chronic diseases like cancer, cardiovascular diseases, and diabetes are on the rise globally. Molecular diagnostics enables earlier and more accurate diagnosis, facilitating timely and targeted treatment. Similarly, infectious diseases—such as HIV, hepatitis, tuberculosis, and, more recently, COVID-19—require rapid diagnosis, which molecular diagnostics can deliver with high precision.

Expansion of Precision Medicine Precision medicine, which focuses on tailoring treatment to the individual, has been a major growth driver. Molecular diagnostics enables the identification of patient-specific mutations and disease markers, leading to personalized treatment plans that improve outcomes. The ability to select targeted therapies is particularly significant in cancer treatment, where one-size-fits-all approaches often fall short.

Technological Advancements The molecular diagnostics market has benefited tremendously from technological advancements. The introduction of digital PCR, automated and high-throughput NGS platforms, and enhanced bioinformatics tools has increased testing speed, accuracy, and affordability. Additionally, advancements in artificial intelligence (AI) and machine learning are enabling better data analysis, predictive modeling, and decision-making.

Growing Demand for Point-of-Care Diagnostics Point-of-care (POC) diagnostics allow for on-the-spot testing, often in non-laboratory environments, which can be particularly valuable in managing diseases in remote or underserved areas. As molecular diagnostics advances in miniaturization and automation, point-of-care molecular tests are becoming increasingly feasible, allowing for broader deployment.

Key Technologies Shaping Molecular Diagnostics

Polymerase Chain Reaction (PCR) PCR is a cornerstone of molecular diagnostics, offering simplicity, rapidity, and affordability. Real-time PCR (qPCR) and reverse-transcriptase PCR (RT-PCR) have been widely used, especially in infectious disease testing. The COVID-19 pandemic highlighted PCR's importance, demonstrating its ability to provide accurate and rapid results.

Next-Generation Sequencing (NGS) NGS enables comprehensive genetic analysis, allowing for the simultaneous sequencing of millions of DNA strands. NGS is pivotal in oncology, where it identifies specific mutations associated with cancers. In infectious disease control, NGS helps trace pathogens and track mutations, proving invaluable in managing outbreaks.

CRISPR-based Diagnostics Though still emerging, CRISPR technology is beginning to influence the molecular diagnostics space, especially in infectious disease detection. CRISPR diagnostics leverages gene-editing technology to identify specific DNA or RNA sequences, offering a high level of precision. CRISPR diagnostics are fast, cost-effective, and highly specific, showing promise in point-of-care settings.

Digital PCR Digital PCR has taken PCR a step further by providing higher accuracy and sensitivity, making it ideal for detecting low-abundance DNA or RNA targets. Digital PCR is particularly useful in cancer mutation testing, where detecting rare mutations or quantifying gene expression levels is necessary.

The Role of Bioinformatics in Molecular Diagnostics

As molecular diagnostics involves analyzing large and complex datasets, bioinformatics has become indispensable. Advanced bioinformatics tools enable faster and more accurate analysis of NGS data, aiding in identifying disease markers, understanding drug resistance mechanisms, and providing clinical decision support. With the integration of AI, bioinformatics tools are evolving to predict disease outcomes, identify patient responses to treatment, and suggest targeted therapies, marking a shift toward predictive diagnostics.

Regional Insights: Global Reach of Molecular Diagnostics

The molecular diagnostics market has established a global presence, with key regions contributing uniquely:

North America is the largest market due to high healthcare spending, advanced infrastructure, and early adoption of cutting-edge technologies.

Europe is significant, driven by high incidences of chronic diseases and government support for molecular diagnostics in preventive care.

Asia-Pacific is the fastest-growing region due to rising healthcare awareness, improving infrastructure, and increasing incidences of infectious diseases. China and India are leading this growth, with a particular focus on infectious disease testing.

Latin America and the Middle East & Africa are also developing markets, with gradual adoption of molecular diagnostics.

Challenges and Future Prospects

Despite its growth, the molecular diagnostics market faces challenges, including:

High Costs The initial setup and ongoing operational costs for molecular diagnostics can be prohibitive, particularly in low-resource settings. Although prices have gradually decreased, high-end equipment like NGS systems remains costly.

Regulatory Hurdles Regulatory approval for molecular diagnostics is rigorous, ensuring safety and efficacy. However, the process can be lengthy, especially for innovative technologies like CRISPR and digital PCR.

Skilled Personnel Shortage Running molecular diagnostic tests often requires skilled personnel, limiting the technology's reach in rural and remote areas. Automated and point-of-care devices are gradually addressing this gap, but more workforce training is necessary.

The Road Ahead for Molecular Diagnostics

The future of molecular diagnostics looks promising, with an increasing shift toward preventive and personalized medicine. The integration of digital health tools, AI, and wearable diagnostics is set to enhance the speed and accessibility of molecular testing. Additionally, as sequencing technology becomes more cost-effective, its adoption in routine diagnostics will likely increase, bringing precision medicine to a broader population.

Pharmaceutical and biotech companies are also investing heavily in molecular diagnostics research, especially in companion diagnostics that guide drug development. This partnership between diagnostics and therapeutics will likely yield personalized, effective treatments that reduce side effects and improve patient outcomes.

Conclusion

The molecular diagnostics market is at the forefront of a healthcare transformation, spearheading a shift from reactive to proactive medicine. With its ability to diagnose diseases at the genetic level, tailor treatments to individual patients, and predict disease trajectories, molecular diagnostics is enabling a more personalized and effective healthcare system. The next decade promises even greater advancements, making molecular diagnostics an exciting field poised to redefine how we understand and treat disease.

[farmacuticals]

Competitive Landscape and Key Players in SNP Genotyping Market

The SNP genotyping and analysis market is witnessing remarkable growth, driven by advancements in genomics and an increasing focus on personalized medicine. SNP (single nucleotide polymorphism) genotyping identifies variations in a single nucleotide in a genome, aiding in the study of genetic predispositions to various diseases, drug responses, and genetic traits. This market includes the technologies, tools, and services used to genotype SNPs and conduct analysis, which has widespread applications in research, diagnostics, and drug development. The demand for SNP genotyping and analysis is particularly high in the fields of oncology, pharmacogenomics, and agricultural research, as it enables deeper insights into genetic variations and their impact on individual and population-level health outcomes.

The SNP Genotyping and Analysis Market Size was projected to reach $13.7 billion (USD billion) in 2022 based on MRFR analysis. It is anticipated that the market for SNP genotyping and analysis will increase from 15.11 billion USD in 2023 to 36.6 billion USD in 2032. During the forecast period (2024-2032), the SNP Genotyping and Analysis Market is anticipated to develop at a CAGR of approximately 10.33%.

SNP Genotyping and Analysis Market Share

The SNP genotyping and analysis market share is primarily held by leading companies like Illumina, Thermo Fisher Scientific, and Bio-Rad Laboratories, which offer state-of-the-art genotyping tools, reagents, and software solutions. These companies dominate the market due to their advanced platforms, broad research capabilities, and established partnerships with research and clinical institutions. New market entrants, however, are gaining a foothold by focusing on cost-effective, high-throughput genotyping solutions. The market share is also geographically diverse, with North America and Europe holding prominent shares due to extensive research funding and a large base of biotech companies, while Asia-Pacific is rapidly growing due to expanding healthcare and research infrastructure.

SNP Genotyping and Analysis Market Analysis

SNP genotyping and analysis market analysis indicates significant growth potential due to the rising prevalence of chronic diseases and the increasing demand for genomic data in clinical and research settings. The analysis also shows that innovations in high-throughput sequencing and bioinformatics are facilitating more efficient, cost-effective SNP genotyping. Technologies like microarray analysis and next-generation sequencing (NGS) are key drivers, providing rapid and accurate SNP data at a fraction of traditional costs. This market analysis highlights the impact of growing awareness of genetic testing among patients and healthcare providers, as well as increasing investments by governments and private entities in genomic research. The focus on personalized medicine, where treatments are tailored to individual genetic profiles, is expected to drive continuous demand in the SNP genotyping and analysis market.

SNP Genotyping and Analysis Market Trends

Key SNP genotyping and analysis market trends include the adoption of automation and AI in genomics. AI-powered data analysis helps interpret large datasets generated by SNP genotyping, enabling faster and more accurate insights into genetic associations. Another trend is the increased use of SNP genotyping in non-invasive prenatal testing (NIPT) and newborn screening, which has become an essential aspect of early disease diagnosis and prevention. Furthermore, the integration of genotyping and bioinformatics platforms enables researchers to conduct more comprehensive analyses, streamlining the identification of disease-related SNPs. The growing interest in consumer genomics, where individuals can gain insights into their ancestry and health risks through direct-to-consumer (DTC) testing kits, is also impacting the SNP genotyping and analysis market.

Reasons to Buy the Reports

Market Insights and Forecasts: Detailed projections on the SNP genotyping and analysis market, including future opportunities and growth drivers.

Competitive Landscape: Comprehensive information on market share and strategic positioning of key players, enabling informed decision-making.

Technological Trends: Insights into the latest technological advancements, such as AI integration, next-generation sequencing, and bioinformatics tools in SNP genotyping.

Regional Analysis: Regional breakdowns and growth potential insights to help investors and companies identify high-opportunity areas globally.

Personalized Medicine Focus: Analysis of the expanding role of SNP genotyping in personalized medicine, highlighting its applications in oncology, pharmacogenomics, and genetic testing.

Recent Developments

Recent developments in the SNP genotyping and analysis market reflect a focus on expanding applications and improving technology. In 2023, Thermo Fisher Scientific launched a new NGS-based genotyping platform designed for high-accuracy pharmacogenomic research, enhancing its utility in personalized medicine. Illumina introduced a cost-effective array platform targeting SNP genotyping for agricultural genomics, providing a tailored solution for crop and livestock breeding. Additionally, Bio-Rad Laboratories announced a strategic collaboration to integrate its genotyping software with AI-powered bioinformatics tools, improving analysis speed and accuracy. Advancements in point-of-care (POC) genotyping devices have also been significant, allowing for rapid SNP analysis in clinical settings and contributing to the increased demand in the SNP genotyping and analysis market.

Related repots:

medical equipment rental market

medical radiation shielding market

membrane filtration market

oral solid dosage pharmaceutical market

[harshnews]

Prenatal Genetic Counselling Market Size, Share, Trends, Growth and Competitive Outlook

"Prenatal Genetic Counselling Market – Industry Trends and Forecast to 2029

Global Prenatal Genetic Counselling Market, By Type (Predictive Testing, Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, Others), Technology (Cytogenetic Testing, Biochemical Testing, Molecular Testing), Application (Chromosome Analysis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, Others) – Industry Trends and Forecast to 2029

Access Full 350 Pages PDF Report @

**Segments**

- **Service Type**: The market can be segmented based on the type of services offered in prenatal genetic counseling such as screening services, diagnostic services, and genetic education services. - **End User**: Another segmentation criterion is based on the end users of prenatal genetic counseling services including hospitals, healthcare clinics, diagnostic centers, and research institutions. - **Mode of Consultation**: The market can also be analyzed by the mode of consultation i.e., whether it is conducted in-person or through teleconsultation services.

**Market Players**

- **Progenity, Inc.**: Progenity is a key player in the prenatal genetic counseling market, offering a range of services including carrier screening, non-invasive prenatal testing, and preimplantation genetic testing. - **Invitae Corporation**: Invitae offers comprehensive genetic testing services including prenatal genetic counseling, carrier screening, and diagnostic testing to healthcare providers and patients. - **Natera, Inc.**: Natera specializes in non-invasive prenatal testing and genetic screening services, providing accurate and reliable results to expectant parents and clinicians. - **PerkinElmer, Inc.**: PerkinElmer is a prominent player in the prenatal genetic counseling market, offering a wide array of genetic testing solutions for prenatal and postnatal care. - **Illumina, Inc.**: Illumina is known for its advanced sequencing and array technologies used in prenatal genetic counseling to assess genetic risks and provide personalized healthcare solutions.

The global prenatal genetic counseling market is witnessing significant growth due to the rising demand for personalized genetic testing services and increasing awareness about genetic disorders among expectant parents. The market segmentation based on service type, end user, and mode of consultation provides valuable insights for industry stakeholders to tailor their offerings and target specific customer segments efficiently. Key market players like Progenity, Inc., Invitae Corporation, Natera, Inc., PerkinElmer, Inc., and Illumina, Inc. are driving innovation and advancements in prenatalThe global prenatal genetic counseling market is experiencing substantial growth, driven by factors such as the increasing demand for personalized genetic testing services and the growing awareness about genetic disorders among expectant parents. The market segmentation based on service type, end user, and mode of consultation allows for a more targeted and efficient approach to meet the needs of specific customer segments within the industry.

The segmentation based on service type, which includes screening services, diagnostic services, and genetic education services, helps in understanding the different aspects of prenatal genetic counseling that are in demand within the market. Screening services are crucial for identifying potential genetic risks early on, while diagnostic services provide accurate assessments for expectant parents to make informed decisions. Genetic education services play a vital role in empowering individuals with knowledge about genetic disorders and their implications.

Another segmentation criterion is based on the end users of prenatal genetic counseling services, which include hospitals, healthcare clinics, diagnostic centers, and research institutions. Understanding the preferences and requirements of these different end users can help market players tailor their services and establish strong partnerships to reach a wider customer base.

Furthermore, the segmentation by the mode of consultation, whether in-person or through teleconsultation services, provides insights into the evolving trends in healthcare delivery. Teleconsultation services are gaining traction due to their convenience and accessibility, especially in remote areas where access to healthcare facilities may be limited. Incorporating teleconsultation services in prenatal genetic counseling can enhance outreach and improve patient engagement.

Key market players such as Progenity, Inc., Invitae Corporation, Natera, Inc., PerkinElmer, Inc., and Illumina, Inc. are at the forefront of driving innovation and advancements in prenatal genetic counseling. These companies offer a wide range of services, including carrier screening, non-invasive prenatal testing, preimplantation genetic testing, and comprehensive genetic testing solutions to cater to the diverse needs of healthcare providers and patients.

In conclusion, the global prenatal genetic counseling market is poised for continued growth and expansion, fueled by technological**Global Prenatal Genetic Counselling Market, By Type (Predictive Testing, Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, Others), Technology (Cytogenetic Testing, Biochemical Testing, Molecular Testing), Application (Chromosome Analysis, Genetic Disease Diagnosis, Cardiovascular Disease Diagnosis, Others) – Industry Trends and Forecast to 2029**

The global prenatal genetic counseling market is experiencing robust growth, driven by factors such as increasing demand for personalized genetic testing services and growing awareness about genetic disorders among expectant parents. Market segmentation based on service type, end user, and mode of consultation offers valuable insights for industry stakeholders to customize their offerings and efficiently target specific customer segments. Key players like Progenity, Invitae Corporation, Natera, PerkinElmer, and Illumina are leading innovation in prenatal genetic counseling, offering a wide array of services to cater to diverse needs.

The segmentation by service type, including predictive testing, carrier testing, prenatal and newborn testing, diagnostic testing, and pharmacogenomic testing, reflects the diverse requirements within the prenatal genetic counseling market. Predictive testing helps identify potential genetic risks, carrier testing assesses the likelihood of passing on genetic disorders, prenatal and newborn testing aid in early diagnosis, diagnostic testing provides accurate assessments, and pharmacogenomic testing personalizes healthcare based on genetic variations.

Technology segmentation, such as cytogenetic testing, biochemical testing, and molecular testing, highlights the different approaches used in genetic

The report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Prenatal Genetic Counselling Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Prenatal Genetic Counselling Market.

Global Prenatal Genetic Counselling Market survey report analyses the general market conditions such as product price, profit, capacity, production, supply, demand, and market growth rate which supports businesses on deciding upon several strategies. Furthermore, big sample sizes have been utilized for the data collection in this business report which suits the necessities of small, medium as well as large size of businesses. The report explains the moves of top market players and brands that range from developments, products launches, acquisitions, mergers, joint ventures, trending innovation and business policies.

The following are the regions covered in this report.

North America [U.S., Canada, Mexico]

Europe [Germany, UK, France, Italy, Rest of Europe]

Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]

South America [Brazil, Argentina, Rest of Latin America]

The Middle East & Africa [GCC, North Africa, South Africa, Rest of the Middle East and Africa]

This study answers to the below key questions:

What are the key factors driving the Prenatal Genetic Counselling Market?

What are the challenges to market growth?

Who are the key players in the Prenatal Genetic Counselling Market?

What are the market opportunities and threats faced by the key players?

Browse Trending Reports:

Asia Pacific Mainframe Market

Asia Pacific Menstrual Cramps Treatment Market

Europe Commercial Cleaning Equipment Market

Europe Mainframe Market

Europe Quantum Computing Market

Europe Tomatoes Market

Europe Utility Locator Market

India Blood Gas Analyzer Market

Middle East And Africa Commercial Cleaning Equipment Market

Middle East And Africa Neurosurgery Market

Middle East And Africa Sports Medicine Market

Middle East And Africa Vaccines Market

Nigeria Cassava Starch Market

Nigeria Starch Processing Market

North America Menstrual Cramps Treatment Market

North America Neurosurgery Market

West Africa Baby Food Market

Antenna Market

Baby Apparel Market

Cassava Starch Market

Castor Oil Market

Cenospheres Market

Coconut Water Market

Collagen Casings Market

Facility Management Market

Functional Confectionery Market

Hemp Seed Market

Infrared Imaging Market

Instant Noodles Market

Laundry Detergents Market

Menstrual Cramps Treatment Market

Micro And Nano Plc Market

Motorcycle Market

Neurosurgery Market

Nickel Alloy Market

Over The Counter Probiotic Supplements Market

Polycystic Kidney Disease Adpkd Market

Private Label Food And Beverage Market

Recreational Cannabis Market

Tofu And Tempeh Market

Tomatoes Market

Vaccines Market

Varnish Makers Market

Wireless Medical Device Connectivity Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 614 591 3140

UK: +44 845 154 9652

APAC : +653 1251 975

Email: corporatesales@databridgemarketresearch.com"

[market-insider]

Preimplantation Genetic Testing Market Future Outlook: Analyzing Size, Share, and Growth Patterns

The global preimplantation genetic testing market size is expected to reach USD 1.54 billion by 2030, growing at 10.3% CAGR from 2024 to 2030, as per the new report by Grand View Research, Inc. Recent technological advancements in testing have changed the current practice of prenatal screening and early detection of chromosomal abnormalities in an embryo. Moreover, the introduction of novel technologies such as NGS, PCR, and FISH is expected to drive market growth over the forecast period.

Growing awareness about genetic diseases and novel techniques for the detection of chromosomal abnormalities and embryo screening for successful IVF holds growth prospects for this vertical over the forecast period. Key market players and service providers such as COOPER SURGICAL, INC. are running awareness campaigns to promote an increased understanding of the diseases and screening of these diseases at the early stages. Such favorable initiatives are expected to increase the demand for PDT in IVF procedures globally.

The increasing adoption of in vitro fertilization (IVF) technique consequently upsurges the utilization of preimplantation genetic testing (PGT). These techniques are advantageous in allowing the development of a healthy fetus and preventing the risk of selective pregnancy termination. Hence, PGT acts as an addendum to assisted reproductive technology.

Moreover, the increased risk of genetic disease in newborns and complications associated with IVF procedures push healthcare providers to recommend PGT. For instance, according to the CDC, in the U.S., about 6,000 babies are born with Down syndrome each year. It is the most common chromosomal condition diagnosed in newborns in the country. Moreover, the high risk associated with aged pregnancy further increases the adoption of PGT worldwide.

Key companies are involved in developing novel methods and solutions to carry out preimplantation genetic diagnosis and screening. To maintain their significant share in the revenue in the coming years, these participants are undertaking strategic initiatives. The strategic undertakings include regional expansion, collaborative development, and new product developments.

For instance, in October 2022, Ovation Fertility and Genomic Prediction partnered to expand genetic testing services by using the LifeView PGT platform for PFT. Moreover, in April 2022, Clevergene received PCPNDT for prenatal genetic testing. The company aimed to expand its services in preimplantation genetic screening and non-invasive prenatal testing.

For More Details or Sample Copy please visit link @: Preimplantation Genetic Testing Market Report

Preimplantation Genetic Testing Market Report Highlights

The rising incidence of genetic diseases has fueled the demand for preimplantation genetic testing (PGT). With increasing prevalence of genetic disorders, PGT has become crucial in IVF procedures.

The Polymerase Chain Reaction (PCR) segment dominated the preimplantation genetic testing market and contributed 39.8% to the market share in 2023. 

The preimplantation genetic diagnosis segment dominated the preimplantation genetic testing market and contributed 77.0% of the market share in 2023.

Europe preimplantation genetic testing market dominated the global market in 2023, capturing the largest revenue share at 40.74%.

Gain deeper insights on the market and receive your free copy with TOC now @: Preimplantation Genetic Testing Market Report

Grand View Research has segmented the global Preimplantation Genetic Testing market on the basis of procedure, product, technology, application, end use, and region.

[omkarpatel]

The Clinical Mass Spectrometry Market is a rapidly growing market owing to increasing applications of mass spectrometry in clinical research and diagnostics

Clinical mass spectrometry finds wide application in clinical research and drug development for disease diagnosis, monitoring disease progression, drug metabolism studies etc. It helps in detection of trace level molecules present in biological samples like blood, urine etc. and provides accurate molecular weight information. The ability of mass spectrometers to perform multitask functions like identification, quantification and structural characterization has increased its demand in clinical settings. The Clinical Mass Spectrometry Market is estimated to be valued at US$ 6.37 Bn in 2023 and is expected to exhibit a CAGR of 26% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market key trends: One of the key trends propelling the growth of clinical mass spectrometry market is increasing adoption of LC-MS/MS systems for newborn screening. Newborn screening involves screening of all newborns for certain genetic, endocrine and metabolic disorders which if left untreated can lead to serious health issues or death. Mass spectrometry based newborn screening allows diagnosis of over 50 different disorders in a single sample analysis. Growing incidences of chronic and genetic diseases is driving the adoption of mass spectrometry for newborn screening procedures globally. Additionally, technological advancements improving resolution, throughput and ease of use of mass spectrometers is supporting their increased adoption in clinical research and disease diagnosis. Porter’s Analysis Threat of new entrants: New companies find it difficult to enter into the market as it requires heavy capital investments for R&D, manufacturing and distribution networks. They also face strong competition from existing key players. Bargaining power of buyers: Buyers have moderate bargaining power as there are many established players providing similar clinical mass spectrometry devices. However, highly differentiated products increase switching costs for buyers. Bargaining power of suppliers: Suppliers have low to moderate bargaining power as key components can be substituted and players have multiple sourcing options to avoid dependence on single/few suppliers. Threat of new substitutes: Threat of new substitutes is low as mass spectrometry technology provides unique capabilities for complex proteomic and metabolomic analysis that are difficult to substitute. Competitive rivalry: Intense as key players compete on performance, pricing and aftersales support. SWOT Analysis Strength: Advanced technologies enabling high throughput screening and accurate detection of biomarkers. Wide applications in R&D, clinical diagnosis and treatment monitoring. Weakness: High installation and maintenance costs limiting adoption in low resource settings. Require highly skilled workforce for operation. Opportunity: Growing proteomic and metabolomic research driving demand. Rising incidence of cancers and other chronic diseases creating avenues. Threats: Stringent regulatory approvals delaying new product launches. Economic slowdowns impacting research spending of pharma companies. Key players operating in the clinical mass spectrometry market are SCIEX AB(US), Thermo Fisher Scientific (US), Agilent Technologies (US), Waters Corporation (US), PerkinElmer Inc. (US), Shimadzu Corporation (Japan), Bruker Corporation (US), Analytik Jena (Germany), JEOL Ltd. (Japan), Hiden Analytical (UK), and MKS Instruments (US), among others. Major players are focusing on new product development and geographical expansion to consolidate their market shares.

[techninja]

The Burden of Sickle Cell Disease in North America: Market Insights

Introduction

Sickle Cell Disease (SCD) is a group of inherited red blood cell disorders that affect millions of people worldwide, with a particularly high prevalence among individuals of African, Hispanic, and Mediterranean descent. In North America, the burden of SCD is significant, with an estimated 100,000 affected individuals. The SCD market in North America is a complex landscape encompassing diagnostics, treatments, and research. This article explores the current state of the North America Sickle Cell Disease market, including advancements, challenges, and opportunities.

Prevalence and Patient Population

SCD primarily affects individuals of African and Hispanic descent, making North America a region with a high prevalence of the disease. In the United States, it is estimated that one in every 365 African American births and one in every 16,300 Hispanic American births result in a child with SCD. These statistics highlight the need for comprehensive care and therapies tailored to the specific needs of the SCD population in North America.

Advancements in SCD Management

1. Disease-Modifying Therapies: Recent years have seen significant advancements in disease-modifying therapies for SCD. Hydroxyurea, the first FDA-approved medication for the condition, has been widely adopted. Newer medications like L-glutamine and voxelotor have also been developed to reduce the frequency of painful vaso-occlusive crises and improve patients' quality of life.

2. Gene Therapies: Cutting-edge gene therapies offer the promise of a cure for SCD. Clinical trials in North America have shown remarkable progress, with some patients achieving substantial reductions in disease severity and anemia. While these treatments are not yet widely available, their development marks a significant advancement in the SCD market.

3. Newborn Screening: Early diagnosis is crucial for effective SCD management. North America has made strides in implementing universal newborn screening programs, ensuring early detection and prompt intervention.

Challenges Facing the Market

1. Healthcare Disparities: Disparities in access to healthcare, especially among minority populations, remain a significant challenge. Many SCD patients face barriers to accessing quality care, leading to unequal health outcomes.

2. Limited Treatment Options: Despite recent advancements, the range of available SCD treatments is still limited. Most therapies aim to manage symptoms rather than cure the disease, leaving room for further research and innovation.

3. High Treatment Costs: The cost of SCD treatment, including medications and hospitalizations, can be substantial. This financial burden can lead to disparities in care and exacerbate the challenges faced by SCD patients.

4. Patient and Caregiver Education: Raising awareness and providing education on SCD is crucial to improving outcomes. Both patients and caregivers need to understand the disease, its management, and the importance of early intervention.

Opportunities for Growth

1. Research and Development: Continued research into disease-modifying therapies and gene editing technologies holds great promise for the North America SCD market. As more innovative treatments become available, patients will have better options for managing their condition.

2. Telemedicine and Remote Monitoring: The COVID-19 pandemic accelerated the adoption of telemedicine, providing an opportunity for SCD patients to access specialized care more easily. Remote monitoring tools can help improve patient outcomes and reduce healthcare disparities.

3. Advocacy and Policy Changes: Advocacy efforts are crucial in shaping healthcare policies and increasing funding for SCD research and patient support. Policy changes can help address healthcare disparities and improve patient outcomes.

Conclusion

The North America Sickle Cell Disease market is a dynamic landscape, with advancements, challenges, and opportunities. While progress has been made in disease management and research, healthcare disparities and limited treatment options persist. Efforts to improve access to care, expand treatment options, and enhance education and awareness are essential to address the unique needs of the SCD population in North America. With continued research and advocacy, the future of SCD management in the region looks promising, offering hope for a better quality of life for those affected by this challenging condition.

Few Other Promising Reports in Medical Devices Industry

Hyperpigmentation Treatment Devices Market

Pigmentation Disorders Treatment Market

Acne Therapeutics Market

Aesthetic Laser Device Market

[potteresque-ire]

Hi :) Are you following the zheng shuang scandal? Would you say that her career is pretty much over now? The rate the news has been unfolding is so crazy to me. It’s only been 3-4 days. Was wondering if the gov would handle her matters personally.

Hello Anon! Yes, I’ve followed the news about the actress, primarily because it offers insight on how the current administration deals with stars exhibiting what it deems as “immoral” behaviour. As of today (2021/01/26), it’s difficult to imagine her career will survive at all. While she isn’t the first to be categorised as a “bad-history entertainer” (劣迹藝人), she’s the first to be explicitly banned by the National Radio and Television Administration (NRTA; 國家廣播電視總局), the department that controls—and censors—content of all radio, television, satellite, and Internet broadcasts in the country. Before, the NRTA didn’t publicise the names of the entertainers the government no longer wishes to see, which allows a possibility for reversal in a few year’s time if the “bad-history” wasn’t too damaging, and production companies are willing to take a risk and produce shows with the entertainers that may be difficult to pass the censorship board. But with such a high profile announcement, the government’s stance is unlikely to turn around in a foreseeable future.

Hmm. Let’s backpedal a little to get everyone on track. Before, I’ve shared some info re: the censoring of books, of audiovisual media. What if the government decides to “cancel” an entertainer instead? How does it do it? What are the standards?

The actress’s downfall is a (sad) example.

I shall skip names, the gossipy elements. Whether she made mistakes or not, no one deserves having their private matters exposed and sensationalised like this; no one should have to undergo such a humiliating, public trial. Essentially, the heart of the story goes as follows: the actress, a romantic-lead type who has been popular for several years, secretly got married. On 2021/01/18, her estranged husband claimed on Weibo that the couple had two children using US-based surrogate mothers, and the actress had abandoned the children in the US under his care. Meanwhile, his friend provided an audio from approximately the 7th month of the surrogate pregnancies, at which time the marriage was already falling apart. In the audio, the actress expressed dismay that abortion was no longer possible; her family talked about abandoning the newborns at the hospital or giving them up for adoption.

The next day (2021/01/19), the actress responded. She didn’t deny the existence of her surrogate children and claimed that she had been extorted. More importantly, she said the following: 

“身為藝人我深知我國疫情的防控與重視。** 在中國國土之上我沒有違背國家的指示，在境外我也更是尊重一切的法律法規。”

“Being an artist, I deeply understand the attention my country (China) has placed on controlling the epidemic. On China’s soil, I didn’t do anything that violates the directives by the government. Outside the country, I’ve been even more respectful of all laws and regulations.”

This apparently hit a nerve of the administration. On the same day (2021/01/19), the Communist Party’s Central Political and Legal Affairs Commission (CPLAC; 中央政法委) — one of the most powerful commissions that oversees the entire legal enforcement system of the government —  published an opinion piece , in which it said:

但[女星姓名]的回应，却通篇强调自己没有违法，丝毫没有任何悔过、道歉的意思。…

But the response of (name of the actress) insists that she didn’t violate any laws, doesn’t show a hint of remorse, regret…

要知道，在我国代孕行为是被明确禁止的。… 作为中国公民，因为代孕在中国被禁止，就钻法律空子就跑去美国，这绝不是遵纪守法。…

It should be known, that in our country, surrogacy is explicitly prohibited … as a PRC (People’s Republic of China) citizen, to use a legislative loophole and go to the US due to the ban of surrogacy in China is absolutely not obeying the law…

要知道，没有营养的炒作带不来长久流量。公众人物的魅力，来自其高尚的职业操守、良好的社会形象、文质兼美的优秀作品，而不是疯疯癫癫、任性胡闹、缺爱卖惨的“人设”。作为公众人物，几度疯狂游走在法律边缘，把这样错乱的世界观、价值观、人生观，置于众目睽睽之下，贻害世风，这绝不是无辜！

It should be known, that hype devoid of significance will not bring in traffic (click rates). The charisma of public figures comes from their noble professionalism, good social image, high quality works in character and content, and not from “personalities” rooting in craziness, petulance, mischief, the selling of one’s lack-of-love and misfortunes. As a public figure, to wildly roam at the edge of the law, to place such wrong and chaotic world views, values and life perspectives in the public eye, to cause harm to the morals of society — that is definitely not innocence!

Things to note here:

1) The CPLAC reacting within a day of the actress’s statement ~  unlikely enough time for teasing out / verifying the facts or truth of the matter.

2) The implication that Chinese citizens must follow Chinese laws, even when they’re overseas. (What about, for example, same-sex marriages?)

3) These words that, IMO, bordered on insult: “craziness, petulance, mischief, the selling of one’s lack-of-love and misfortunes”.

The actress’s career was hanging by a thread with this opinion piece. State-controlled agencies chimed in, many of which echoing CPLAC’s stance that surrogacy is explicitly prohibited in China. By night time of 2021/01/19, rumours abounded that multiple media companies had already listed the actress as a “bad-history entertainer” and would be shelving all her works and cancelling all her scheduled appearances. Prada terminated her endorsement.

The final drop of the hammer happened a day later, in the evening of 2021/01/20. The NRTA issued a statement that explicitly named the actress and contained the following lines:

代孕不是私事，与法不合，有违社会主义公德。…

Surrogacy isn’t a private matter. It doesn’t agree with the law, violates the civility of socialism…

从事广播电视和网络视听的演艺人员尤其是知名艺人，作为公众人物，有很大的社会影响力和示范作用，应当自觉践行行业自律准则，严格律己修身，严私德，讲大德，守公德。

Artists who work in TV and web audiovisual productions, especially famous entertainers, have significant social influence and demonstrative roles as public figures. They should be conscious about the self-discipline required for their industry, be strict in their behaviour and personal virtues, speak of great kindness and defend civility.

行业主管部门的相关政策要求是明确的，严格的。广大人民群众不愿意、不接受、也不允许丑闻劣迹者污染我们的社会公德和公序良俗。

Policies regarding the management of the industry is clear and strict. The public does not want, does not accept, does not allow those with scandals and poor history pollute the civility, the good order and customs of our society.

我们不会为丑闻劣迹者提供发声露脸的机会和平台，一如既往，坚决为广大人民群众提供健康向上荧屏声频。

We will not supply opportunities and platforms for those with scandals and poor history to sound their opinions, to show their faces. Just as before, we are determined to provide audiovisual content that is healthy above all.

And just like this, less than 72 hours after the estranged husband posted on his Weibo, the actress’s career is over. The NRTA, which has The Say on who and what get exposure time on screen, has spoken. The actress had no way of self-defence. Her 11 million followers on Weibo didn’t get to decide whether she’d stay or she’d go.

This is a brutal punishment but for what, exactly? Some netizens have whispered while the others shout their condemnations ~ but I thought…. surrogacy isn’t illegal?

And they’re correct: surrogacy isn’t explicitly outlawed in China, despite what CPLAC and other state agencies has claimed. In 2001, the Ministry of Health banned medical institutions and health care workers from "practicing any form of surrogate technology". However, no laws have ever passed that prohibit individuals from commissioning or providing surrogacy services—especially when the services are overseas.

The actress, therefore, wasn’t lying when she said she didn’t do anything that violates the directives by the government on China’s soil. Her “crime” of using surrogate mothers was, at worst, a legally grey area. For years, China has had a booming, semi-underground surrogacy market, their client base including older parents who wish to have another child after the country relaxed its birth limit (the so-called “one-child policy”) in 2015, infertile couples, and to a lesser extent, the LGBT+ community. Blued, China’s most popular gay social networking/dating app, has offered overseas surrogate services for several years that connect their clients with US-based surrogates. It pulled the services after the actress’s incident.

But all that doesn’t matter. People in China understands this: the law book is there, but those in power at the moment always have the final word ~ and that word doesn’t have to match the legal codes, or the previous final words of their predecessors. As for the moral outcry re: the actress having wished to abort / give up her unborn children, it’s worth mentioning abortion has long been used to to enforce the country’s decades-long birth limit policies, and forced, violent late-term abortions were not unheard of. Many people in China are also aware of that.

But again, it doesn’t matter.

I’ve described the government’s reactions in detail because they put in words the expectations it has of its entertainers. Entertainers in China are expected to not only obey the laws, but also have proper world views, (moral) values and life perspectives (collectively called 三觀, literally, “three views”) as defined by the government. The state has also made clear that such expectations grow with the fame of the entertainers.

Entertainers at the top of the c-ent industry, especially the idol types with many young fans, are therefore expected to get things right. These opinion pieces are reminders that the administration keeps a close eye on them, can “cancel” them with a few words if they fail.

The term for “canceling” an entertainer is 封殺 (literally, “seal and kill”).

The actress isn’t the first to be “cancelled” by the government. The first time the NRTA issued a directive regarding “poor-history entertainers” (劣迹藝人) was in 2014, which essentially called for shutting out any entertainer with a history of bad behaviours. It demanded all production companies, TV stations, online media companies and theatres to stop producing / broadcasting audiovisual content with these people, citing that TV and film media should be used for “spreading the progressive culture of socialism and promoting socialist core values” (”传播社会主义先进文化、弘扬社会主义核心价值观”). As these entertainers will no longer be exposed to an audience, these directives effectively kill the career of most who are affected.

What makes up the “poor-history” of “poor-history entertainers” then?

- The 2014 edition named drug use and prostitution (including hiring a prostitute) specifically.

- The 2018 edition, an announcement made by a top NRTA official, stated that audiovisual programmes should adhere to the “Four Never-Use” guidelines when inviting guests for their shows. Those guidelines were vague but for the last line: “In addition, the NRTA explicitly requests that programmes should not use entertainers with tattoos; (those associated with) hip-hop culture, sub-cultures (non-mainstream cultures), decadent cultures.” (”另外，总局明确要求节目中纹身艺人、嘻哈文化、亚文化（非主流文化）、丧文化（颓废文化）不用。”)

Some may be asking: wait … hip-hop?

Yes.

It was believed that hip-hop artists were targeted due to a scandal at the time, in which (another) well-known actress had an extra-marital affair with a rapper. Analysis of the rapper’s lyrics found sexism and suggestions of drug use (the rapper later apologised and claimed his “core values” had been distorted due to influence from “black music”.) 

As this guideline hasn’t been retracted under any formal capacity, it can still be used to axe any show, shut out any entertainer.

If you’re wondering about SDOC, for example, this again illustrates the need for some … mind-reading skills to navigate life in China. A good way to achieve that without superpowers is to have the right connections to higher-ups, who can offer hints on what can get away at the moment and what cannot (this is true not only for c-ent, but for most business practices in the country; building 關係 guanxi— literally, “relationship”— is a must for those who wants a  piece of the Chinese market).

- In 2020, NRTA expanded the “no exposure” rule to live-stream shows on the internet as well as on- and offline charity events, where previously “cancelled” artists had started to find jobs in to make a living. While that notice didn’t further elaborate on what makes “bad history”, the accompanying article in People’s Daily (The State-controlled Newspaper) went into more details. In addition to drug use and prostitution specified in 2014, the article named tax evasion; lying about education levels; *suspected* (涉嫌) extramarital affairs, domestic violence and inappropriate speech.

It’s worth emphasising that many of these activities are not illegal. “Suspected” also means these activities do not have to have happened ~ it’s the impression that they’ve happened that counts. Hence, back to the actress who had surrogate children, not only did it not matter whether surrogacy is actually illegal, it didn’t matter whether the leaked audio was real or taken out of context, or that the babies didn’t end up being aborted / adopted. The article once again stresses that private matters are no longer private for entertainers who are in the public eye as social influencers, and these directives on “poor-history entertainers” — colloquially called “封殺令”, with 封殺 meaning the “seal-and-kill” and 令 meaning command (as in Chen Qing Ling 陳情令) — are there to set the standards, the bottom-line for c-ent. It did call for more specifics in future directives: more guidance on what makes “bad history”, the ways these entertainers can redeem themselves. As of today, however, such specifics have not been provided. As a result, to avoid crossing the NRTA, the media has ended up “overachieving” in certain cases, wiping out the screen time of entertainers who only have a remote chance of being viewed as having “bad history” to play it safe. Last October, for example, a young singer was briefly edited out of all his recorded shows because his parents (not him) was revealed to be deadbeats owing millions in debt.

And so, without a known way out yet, “bad-history” entertainers such as the actress will likely remain “sealed and killed” for a long time. Entertainers recently caught with extramarital affairs ~ a relatively minor “offence” ~ have been missing on screen for 2-3 years, and the heavy-handed treatment by the government this time is likely to put a pause on any companies considering using these people again. Even if they’re finally allowed some degree of comeback, their career prime will be over and and their NRTA “sentence” will likely follow them everywhere they go, which makes their getting face time in any high-profile (high-investment) projects unlikely. Those who must work to make their ends meet will probably end up like so many entertainers who never made it big, or are at the very tail end of their career ~ drifting from city to city singing in local clubs, getting paid poorly and harassed by rude customers...

===

** A side note: In case anyone wonders why she brought up COVID, it’s a similar idea as Gg apologising for “佔用了一些社會公共資源” “occupying social resources” in his first team post after 227 (2020/03/01). For an authoritarian regime that has placed the most attention on maintaining social stability (ie. quelling dissent), disrupting the government’s narrative re: current events and potentially reversing the overall tone the administration is trying to reach in public discourse can be a greater offence than any actual “wrongdoing”. 227, as an incident, was guilty of that.

(And I’m bringing this up because I find this relevant to the safety asks I have in my inbox. Arguments among fans do not themselves render Gg and Dd unsafe, but can become a significant issue if they “occupy social resources”, disrupt the government’s narratives and/or its political machinery in some ways. IMO, 227 took a dangerous turn not because the fans were arguing over a piece of fanfic, but because a group of fans took over the reporting machinery intended to rat out dissidents. It was a mistake that I hope no fans ~ regardless of who they support ~ will repeat again.)

[rohit890]

Newborn Screening Market Key Players, Share, Trends, Sales, Segmentation And Forecast To 2031

Market Overview

The global newborn screening market was valued at USD 1.7 billion in 2021 and it is anticipated to grow up to USD 3.7 billion by 2031, at a CAGR of 8.0% during the forecast period.

Newborn screening identifies conditions that can affect a childs long-term health or survival. This screening technology includes a series of tests essential for timely detection, early diagnosis, and health management to prevent overall disability and avert death of a child. These tests are performed shortly after the baby is born, and detect genetic, developmental, and metabolic disorders in newborn babies. Newborn screening is done by using a few drops of blood from the newborn’s heel, for certain genetic, endocrine, and metabolic disorders, and are tested for hearing loss and critical congenital heart defects (CCHDs) prior to discharge from a hospital or birthing center.

View Detailed Report Description: https://www.globalinsightservices.com/reports/newborn-screening-market/

Market Dynamics

The prevalence of newborn diseases has risen in recent years, prompting providers to raise awareness and support the demand for advanced screening instruments. Hearing, metabolic, and hormonal disorders and critical congenital heart disease are the major newborn disorders; most are treatable if diagnosed early. For instance, according to the US CDC, during 2015–2017, the prevalence of newborn disorders was 34 per 10,000 live births in the US. Approximately 12,900 infants are expected to be identified each year with a disorder. Moreover, according to the same source, the most prevalent disorders are hearing loss (16.5 per 10,000), congenital hypothyroidism (6.0 per 10,000), sickle-cell disease (4.9 per 10,000), and cystic fibrosis (1.8 per 10,000). Such scenario will propel the industry growth.

Several ethical concerns related to prenatal and new-born testing may hamper the market progression. Prenatal and new-born genetic testing raises complex ethical issues further limiting the development of clinical services and implementation of public policy related to access and funding. The use of screening in selective abortion has raised several concerns. The rising occurrence of false results in prenatal and new-born genetic testing might decrease the adoption of genetic testing. For instance, around 5% of women are tested false-positive during prenatal testing for Down syndrome.

Get Free Sample Copy of This Report: https://www.globalinsightservices.com/request-sample/GIS10337

The key players in the market are PerkinElmer (US), Demant A/S (Denmark), Natus Medical (US), Bio-Rad Laboratories (US), Danaher Corporation (US), Medtronic (Ireland), Chromsystems Instruments & Chemicals GmbH (Germany), Trivitron Healthcare (India), Baebies (US) and Recipe Chemicals+Instruments (Germany), among others.

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

Contact Us:

Global Insight Services LLC

16192, Coastal Highway, Lewes DE 19958

E-mail: info@globalinsightservices.com

Phone: +1–833–761–1700

[the-rachana]

Digital Genome Market Is Thriving Worldwide – BioMérieux, Inscripta Inc., Agilent Technologies Inc., F. Hoffmann-La Roche Ltd.

The scientific community has tried to address genetic susceptibility and severity to SARS-CoV-2 infection by combining research efforts using existing genetic databases. Multiomic-based approaches and genome-wide association studies (GWAS) have been employed to uncover biological networks and common variants underlying host-pathogen interactions. Similarly, data derived from genomes, such as polygenic risk scores (PRS), ABO blood groups, and HLA haplotypes, can be potentially used to decipher COVID-19 complications, resistance, and susceptibility.

The global Digital Genome market reached ~US$ 12.1 billion in 2021. The market is expected to witness a CAGR of 10% from 2022 to 2030.

Prenatal genetic screening programs are likely to grow at a significant pace. This is because these programs help expectant mothers identify chromosomal anomalies in their offspring. Moreover, it is anticipated that in the next 10 years, every newborn’s genome would be sequenced and stored in the electronic medical record. Gauging the future market potential of genomics in newborn screening programs, emerging companies like Counsyl and Natera have launched various genetic tests to maintain their competitive edge in the market.

Get a Sample PDF of the Report - https://growthplusreports.com/inquiry/request-sample/digital-genome-market/7910

Key Players

·         BioMérieux

·         GenMark Diagnostics, Inc.

·         Illumina, Inc.

·         Thermo Fisher Scientific

·         NanoString Technologies, Inc.

·         Inscripta Inc.

·         GE Healthcare Genomic Health, Inc.

·         Pacific Bioscience, PerkinElmer Inc.

·         Qiagen Quest Diagnostics

·         Agilent Technologies Inc.

·         Becton, Dickinson and Company

·         F. Hoffmann-La Roche Ltd.

·         Regeneron Pharmaceuticals, Inc.

  By Product Type  

·         Sequence & Analysers Instruments

·         DNA/RNA Analysis kits

·         Sequencing & Analysis Software

·         Sample Preparation Instrument

By Application

·         Microbiology

·         Reproductive & Genetic

·         Transplant & Agriculture

·         Forensics

·         Research & Development

Key Reasons to Purchase:

(1)   To gain insightful analyses of the market and have a comprehensive understanding of the global market and its commercial landscape.

(2)   Assess the production processes, major issues, and solutions to mitigate the development risk.

(3)   To understand the most affecting driving and restraining forces in the Digital Genome Market and its impact in the global market.

(4)   Learn about the market strategies that are being adopted by leading respective organizations.

(5)   To understand the outlook and prospects for the market.

Key Questions Answered in the Report Include:

(1)   This report gives all the information about the industry analysis, revenue, and overview, of this market.

(2)   What will be the rate of increase in market size and growth rate by the end of the forecast period?

(3)   What are the major global Digital Genome Market trends influencing the development of the market?

(4)   What are the vital results of SWOT analysis of the major players operating in the Digital Genome Market?

(5)   What are the potential growth opportunities and threats faced by Major competitors in the market?

TOC of Digital Genome Market

1 Scope of the Report

1.1 Market Ecosystem

1.2 Geographic Scope

1.3 Timeline Under Consideration

1.4 Market Research Methodology

1.5 Research Process and Data Source

1.6 Economic Indicators

1.7 Currency Considered

2 Digital Genome Market Executive Summary

2.1 World Market Overview

2.1.1 Global Market Size 2022-2030

2.1.2 Market Size CAGR by Region 2020 VS 2028

2.2 Digital Genome Market Segment by Type

2.2.1 Type 1

2.2.2 Type 2

Browse the full report now: https://growthplusreports.com/report/digital-genome-market/7910

About us

Growth+Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth+ portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis, and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.

[vynzresearchindia]

Global Newborn Screening Market Size, Share and Demand Forecast Report by 2027 | VynZ Research

The Global Newborn Screening Market was value at US$ 0.85 billion in 2020 and it is expected to grow with a strong CAGR of 7.8% during the 2021-2027. In order to achieve the targeted revenue, the market report employs significant and insightful statistics of historical and forecasted data based on growth drivers, challenges and restraints. The report also evaluates the opportunities including technical and government supports for the entrants to joins the market comprehensively.

According to the VynZ Research, the Global Newborn Screening Market size is sub-divided into multiple segments and each segment-wise analysis provides details regarding reasons behind the segment-wise expansion, CAGR, volume, revenue, production, consumption, sales, manufacturing cost, pricing, factors affecting the geographical growth rate.

Get a sample copy of the market analysis report: https://www.vynzresearch.com/healthcare/global-newborn-screening-market/request-sample

The list of major key players of the Global Newborn Screening Market is mentioned in "Competitive insight" along with a thorough overview of their strategies and contribution to the growth plan. Additionally, it provides details on the advantages and disadvantages, institutional growth, cutting-edge discoveries, mergers and acquisitions, expansion plans, footprint, market presence, and product portfolios of the key rivals in the market. Some of the leading market players covered in this global market report are: -

PerkinElmer

Demant A/S

Natus Medical

Bio-Rad Laboratories

Danaher Corporation

Medtronic

Chromsystems Instruments & Chemicals GmbH

Trivitron Healthcare

Baebies

Recipe Chemicals+Instruments

Market segment

This report bifurcates the global market into following categories: -

By Test

Robotic Systems

Services

By Technology

Inspection and Measurement

Object Reconstruction

Projection and Navigation

Reporting and Virtualization

Others

Reason to buy this report

This research report is unbiased and gives the deep insight of market statistics including information on the main market trend and the projected size of the worldwide market based on regional and competitive analyses. The growth of the market has been aided by a number of variables, which are also discussed in this market research report. The report also covers the most innovative and effective techniques for gathering, compiling, estimating, and analyzing market data.

Explore more reports by VynZ Research

Global Wound Dressing Market – Analysis and Forecast (2021-2027)

Global Smart Home Healthcare Market – Analysis and Forecast (2021-2027)

Global Pulse Oximeter Market - Analysis and Forecast (2021-2027)

Global Beauty Devices Market – Analysis and Forecast (2022-2030)

[prabha194]

Prenatal and Newborn Genetic Testing Market Opportunity Assessment, Market Challenges, Key vendor analysis, Vendor landscape by 2027

According to The Insight Partners market research study titled “Prenatal and Newborn Genetic Testing Market - Global Analysis and Forecasts by Product, Disease Indication and End User”. The Global Prenatal and Newborn Genetic Testing Market is expected to reach US$ 11,204.7 Mn in 2027 from US$ 4,034.4 in 2018. The market is estimated to grow with a CAGR of 12.2% from 2019-2027. The report highlights the trends prevalent in the global prenatal and newborn genetic testing market and the factors driving the market along with those that act as deterrents to its growth.

The key factors that are driving the growth of the significant increase in the prevalence of genetic diseases among infants, supportive government for promoting the use of prenatal and newborn testing and increasing birth rate are boosting the market over the years. In addition, the growth opportunities in emerging markets in developing countries are likely to have a positive impact on the growth of the market in the coming years.

Request Copy of Prenatal and Newborn Genetic Testing Market Growth Report https://www.theinsightpartners.com/sample/TIPBT00002550/

Several types of genetic diseases affect the fetuses in the womb. The way in which these genetic diseases are inherited helps to determine the risk that they pose on pregnancy as well as the risk of its recurrence. The risk of having genetic diseases in babies is high in cases where the parents have another child with a genetic disease, family history of a genetic disorder, or if either of a parent has a chromosomal abnormality. There is a significant prevalence of genetic diseases among infants. Moreover, these diseases are also responsible for infant mortality across the globe. For instance, according to the World Health Organization 2016, an estimated 7.9 million infants across the world are born with genetic defects. Moreover, according to the Centers for Disease Control and Prevention (CDC), birth defects affects every 1 in 33 babies born in the US. On the other hand, chromosomal abnormalities such as Down syndrome affects 1 in 691 babies born in the US, as per the CDC’s data in 2017. Thus, the high prevalence of genetic diseases among infants account for the increasing demands for prenatal and newborn genetic tests, thereby contributing to the growth of the market.

Global Prenatal and Newborn Genetic Testing Market was segmented by product, disease indication, and end user. The product segment was further divided as diagnostic and screening. On the basis of disease indication, the market is segmented into the cystic fibrosis, sickle cell anemia, Down syndrome, phenylketonuria, and other diseases. Based on the end user, the prenatal and newborn genetic testing market is segmented into hospitals and clinics, diagnostic centers, other end users. The hospitals and clinics held a major market share among the end user segment as they are the primary healthcare centres for all patients. 

Some of the major primary and secondary sources included in the report for the Prenatal and Newborn Genetic Testing Market are the World Health Organization, UAE Genetic Diseases Association, Centre for Arab Genomic Studies, National Health Service (NHS), Centers for Disease Control and Prevention, National Human Genome Research Institute (US), Florida Department of Health and others.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us: Contact Person: Sameer Joshi  Phone: +1-646-491-9876

[market-inquiry]

Newborn Screening LC MS Reagent Kits Market Industry in UK Size, Growth, Report Study, Demand, Key Players, and Forecast by 2029

Newborn Screening LC MS Reagent Kits Market Research Report 2022-2029 The Global Newborn Screening LC MS Reagent Kits Market Research Report involves an ideal combination of primary and secondary research with the help of which the experts’ inferences and calculations are derived. Our reports are revised at regular intervals to be able to give recent information to our clients and help them make efficient business decisions. The information provided in the reports is verified in terms of quality and reliability.

The Major Players Covered in this Report: Prominent Players Active in the Market- PerkinElmer Inc., Chromsystems Instruments & Chemicals GmbH, Zivak Technologies, Tech. Dev. Pte. Ltd (SCIEX), RECIPE Chemicals, and Labsystems Diagnostics Oyare some of the key players leading theglobal newborn screening LC-MS reagent kits market.

Get a Sample PDF Report: https://straitsresearch.com/report/Newborn-Screening-LC-MS-Reagent-Kits-market/request-sample

Newborn Screening LC-MS Reagent Kit MarketSegmentation- By Type- Derivatized, Non derivatized, By Sales Channel- Protein Metabolism, Fatty Acid Metabolism, Organic Acid Metabolism, Others

The report specifically highlights the Newborn Screening LC MS Reagent Kits Market Research Report share, company profiles, regional outlook, product portfolio, a record of the recent developments, strategic analysis, key players in the market, sales, distribution chain, manufacturing, production,  new market entrants as well as existing market players, advertising, brand value, popular products, demand and supply, and other important factors related to the Newborn Screening LC MS Reagent Kits Market Research Report to help the new entrants understand the market scenario better.

Important factors like strategic developments, government regulations, Newborn Screening LC MS Reagent Kits Market Research Report analysis, end-users, target audience, distribution network, branding, product portfolio, market share, threats and barriers, growth drivers, latest trends in the industry are also mentioned.

Regional Analysis For Newborn Screening LC MS Reagent Kits Market Research Report:

North America (United States, Canada, and Mexico) Europe (Germany, France, UK, Russia, and Italy) Asia-Pacific (China, Japan, Korea, India, and Southeast Asia) South America (Brazil, Argentina, Colombia, etc.) Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

In this study, the years considered to estimate the market size of the Newborn Screening LC MS Reagent Kits are as follows:

• History Year: 2014-2019 • Base Year: 2019 • Estimated Year: 2020 • Forecast Year 2022 to 2029

The main steps in the investigation process are:

1) The first step in market research is to obtain raw market information from industry experts and direct research analysts using primary and secondary sources.

2) Extracts raw data from these sources to extract valuable insights and analyze them for research purposes.

3) Classify the knowledge gained by qualitative and quantitative data and place it accordingly to make final conclusions.

Key Questions Answered in the Report:

• What is the current scenario of the Global Newborn Screening LC MS Reagent Kits Market Research Report? How is the market going to prosper throughout the next 6 years? • What is the impact of COVID-19 on the market? What are the major steps undertaken by the leading players to mitigate the damage caused by COVID-19? • What are the emerging technologies that are going to profit the market? • What are the historical and the current sizes of the Global Newborn Screening LC MS Reagent Kits Market Research Report? • Which segments are the fastest growing and the largest in the market? What is their market potential? • What are the driving factors contributing to the market growth during the short, medium, and long term? What are the major challenges and shortcomings that the market is likely to face? How can the market solve the challenges? • What are the lucrative opportunities for the key players in the Newborn Screening LC MS Reagent Kits Market Research Report? • Which are the key geographies from the investment perspective? • What are the major strategies adopted by the leading players to expand their market shares? • Who are the distributors, traders, and dealers of the Global Newborn Screening LC MS Reagent Kits Market Research Report? • What are sales, revenue, and price analysis by types and applications of the market?

For More Details On this Report: https://straitsresearch.com/report/Newborn-Screening-LC-MS-Reagent-Kits-market

About Us:

Regardless of whether you're looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with what customers purchase. We overcome the issues of our customers by recognizing and deciphering just the target group, while simultaneously generating leads with the highest precision. We seek to collaborate with our customers to deliver a broad spectrum of results through a blend of market and business research approaches. This approach of using various research and analysis strategies enables us to determine greater insights by eliminating the research costs. Moreover, we're continually developing, not only with regards to where we measure, or who we measure but in how our visions can enable you to drive cost-effective growth.

Contact Us:

Company Name: Straits Research Email: sales@straitsresearch.com Phone: +1 646 480 7505 (U.S.) +91 8087085354 (India) +44 208 068 9665 (U.K.)

[clevertimetravelpaper]

Dried Blood Spot Collection Cards Market analysis, scope, market overview. Industry, Company, Key Players, Technology, Trends, Share and Forecast

The market for dried bloodstain collection cards is expected to witness market growth during the forecast period of 2020 to 2027. Data Bridge Market Research analyzes the market to consider a CAGR of 3.10% during the aforementioned forecast period. Dried blood spot cards are used when newborns are screened for congenital disorders or metabolic disorders. The dried blood spot test is a biological swab in which blood samples are dried and blotted on filter paper because it is minimally invasive. These samples are then transported under ambient conditions to an analytical laboratory for the necessary analyses. Applications of dried bloodstain collection cards are systems biology, drug development, forensics,

The increased use of dried blood spots for the diagnosis of autoimmune diseases and infectious diseases is driving the growth of the market. By using dried blood spots, it helps to provide efficient and early diagnosis, facilities such as a convenient alternative to plasma-based tests, easy storage and collection with limited laboratory capacity and stimulates the growth of the market. The advantages are low cost, easy collection and storage and short diagnostic period, high accuracy and others will create new opportunities for the Dried Blood Spot Collection Card market segmented during the period of forecast 2020-2027.

Get Sample PDF of the Report – https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-dried-blood-spot-collection-cards-market

Key Players Covered in Dried Blood Spot Collection Cards Market Report F. Hoffmann-La Roche Ltd, QIAGEN, Shimadzu Scientific Instruments, Eastern Business Forms, Inc, PerkinElmer Inc, Ahlstrom,-Munksjo, Pall Corporation, ARCHIMED Life Science GmbH, CENTOGENE NV, Surgeine Healthcare (India) Pvt, Ltd, Hemaxis, Lipomic Healthcare, Thomas Scientific and Gentegra LLC, among other national and global players. Market share data is available separately for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America . DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

This Dried Blood Spot Collection Card Market report provides details about recent new development, trade regulation, import and export analysis, production analysis, supply chain optimization value, market share, impact of domestic and localized market players, analysis of opportunities in terms of emerging revenue pockets, changes in market regulations, strategic analysis of market growth, market size , category market growth, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market.To get more insights on the Data Bridge Market Research Dried Blood Spot Collection Cards Market, contact us for an Analyst Brief, our team will help you make an informed market decision to achieve the growth of the market.

To get more insights into Market Analysis, Browse Research Report Summary @ – https://www.databridgemarketresearch.com/reports/global-dried-blood-spot-collection-cards-market

Global  Dried Blood Spot Collection Cards   Market Scope  and Market Size

The dried bloodstain collection card market is segmented on the basis of application and type of card. The growth among these segments will help you analyze low growth segments within the industries and provide users with valuable market insight and market insights to help them make strategic decisions for identification of major market applications.

Based on application, the dried blood spot collection card market is segmented into newborn screening, infectious disease testing, therapeutic drug monitoring, forensics and others.

Based on card type, the dried bloodstain collection card market is segmented into whatman 903, ahlstrom 226, FTA and others.

Country-Level Analysis of the Global  Dried Blood Spot Collection Cards Market 

The Dried Blood Spot Collection Card market is analyzed and market size insights and trends are provided by country, application and card type as listed above. Countries covered in the Dried Bloodstain Collection Cards market report are US, Canada & Mexico North America, Germany, France, UK, Netherlands , Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia , Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Saudi Arabia, United Arab Emirates, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) in Middle East and Africa (MEA) executive,

North America dominates the dried blood spot collection card market owing to high demand for newborn screening, growing number of babies, rise in HIV and other diseases.

Browse Complete TOC at-   https://www.databridgemarketresearch.com/toc/?dbmr=global-dried-blood-spot-collection-cards-market

The country section of the Dried Blood Spot Collection Cards market report also provides individual market impacting factors and regulatory changes in the country market that impact current and future trends in the market. market. Data points such as consumption volumes, production sites and volumes, import and export analysis, price trend analysis, raw material cost, value chain analysis Downstream and Upstream are some of the major indicators used to forecast the market scenario for each country. 

Top Healthcare Report Links:-

About Data Bridge Market Research:

One absolute way to predict what the future holds is to understand today's trend! Data Bridge Market Research presented itself as an unconventional and neoteric market research and consulting company with an unparalleled level of resilience and integrated approaches. We are committed to unearthing the best market opportunities and fostering effective information for your business to thrive in the market. Data Bridge strives to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process. Data Bridge is a suite of pure wisdom and experience that was formulated and framed in 2015 in Pune.

Data Bridge Market Research has over 500 analysts working across different industries. We have served over 40% of Fortune 500 companies globally and have a network of over 5,000 clients worldwide. Data Bridge is expert in creating satisfied customers who rely on our services and rely on our hard work with certainty. We are pleased with our glorious 99.9% customer satisfaction rating.

Contact us:-

Data Bridge Market Research

USA: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:-   corporatesales@databridgemarketresearch.com

[qualitativemarketanalysis]

The Best Advice You Could Ever Get About Europe Genetic Testing Market  and their future opportunities

Europe Genetic Testing market was valued at US$ 2,472.0 Mn in 2020 and it is projected to reach at US$ 4,262.4 Mn by 2027, at a CAGR of 8.5% during the forecast period.

 Major factors accounting for this growth include the increase in incidences of genetic, infectious & chronic diseases, reduction in prices of genetic sequencing, rising adoption of precision medicine diagnostic techniques. Genetic testing is defined as medical test which detect changes in proteins, genes or chromosomes. The test results are able to confirm a speculated underlying genetic condition or aid in determining an individual’s chance of developing/ passing on a genetic disorder.

 The  Europe Genetic Testing market  has explored some key dynamics which have a solid influence during this forecast period. This report studied the market trends, value trends, volume trends, and the pricing history of the market. Also, report covers different market driving factors, restraining factors, and opportunities to gain an insightful understanding of the market.

Get Free Sample Copy of This Report @ https://qualiketresearch.com/request-sample/Europe-Genetic-Testing-Market/request-sample

Market Key Players

 Various key players are listed in this report such as Abbott Laboratories, Illumina Inc., Eurofins Scientific, Qiagen, Elitech Group, Thermo Fischer Scientific, Centogene AG, Blueprint Genetics, 23andMe Inc., F. Hoffmann-La Roche Ltd, etc.

 Market Taxonomy

 By Type

Carrier Testing

Diagnostic Testing

Newborn Screening

Predictive &     Presymptomatic Testing

Prenatal Testing

Others

 By Disease

Alzheimer's Disease

Cancer

Cystic Fibrosis

Sickle Cell Anemia

Duchenne Muscular     Dystrophy

Thalassemia

Huntington's Disease

Others

 By Technology

Cytogenetic Testing

Biochemical Testing

Molecular Testing

 By Country

Germany

UK

France

Turkey

Switzerland

Norway

Sweden

Spain

Italy

Denmark

Finland

Iceland

Poland

Luxembourg

Netherlands

Belgium

Get full Study @ https://qualiketresearch.com/reports-details/Europe-Genetic-Testing-Market

About Us

 QualiKet Research is a leading Market Research and Competitive Intelligence partner helping leaders across the world to develop robust strategy and stay ahead for evolution by providing actionable insights about ever changing market scenario, competition and customers. QualiKet Research is dedicated to enhancing the ability of faster decision making by providing timely and scalable intelligence. We use different intelligence tools to come up with evidence that showcases the threats and opportunities which helps our clients outperform their competition. 

[biotecnika]

PerkinElmer Biochemistry Application Scientist Job – MSc & PhD Apply PerkinElmer is a global technology leader driving growth and initiative in the Environmental and Human Health Science markets. PerkinElmer Genomics is one of the world’s largest providers of newborn screening services and offers comprehensive genetic testing solutions that help provide insight into the complex nature of […] The post PerkinElmer Biochemistry Application Scientist Job – MSc & PhD Apply appeared first on BioTecNika .